2015
Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): Association of biomarkers with clinical outcomes.
Choueiri T, Fishman M, Escudier B, McDermott D, Kluger H, Stadler W, Perez-Gracia J, McNeel D, Curti B, Harrison M, Plimack E, Appleman L, Fong L, Drake C, Young T, Chasalow S, Ross-Macdonald P, Simon J, Walker D, Sznol M. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): Association of biomarkers with clinical outcomes. Journal Of Clinical Oncology 2015, 33: 4500-4500. DOI: 10.1200/jco.2015.33.15_suppl.4500.Peer-Reviewed Original Research
2014
Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial.
Choueiri T, Fishman M, Escudier B, Kim J, Kluger H, Stadler W, Perez-Gracia J, McNeel D, Curti B, Harrison M, Plimack E, Appleman L, Fong L, Drake C, Cohen L, Srivastava S, Jure-Kunkel M, Hong Q, Kurland J, Sznol M. Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial. Journal Of Clinical Oncology 2014, 32: 5012-5012. DOI: 10.1200/jco.2014.32.15_suppl.5012.Peer-Reviewed Original Research